b-D-葡萄吡喃糖,1,6-脱水-6-C-(苯基硫代)-,2,4-二乙酸酯,(R)-(9CI) | 75210-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: b-D-葡萄吡喃糖,1,6-脱水-6-C-(苯基硫代)-,2,4-二乙酸酯,(R)-(9CI)
• 中文别名: 4-乙基-1-哌嗪基l
• 英文名称: 4-Ethylpiperazin-1-ol
• 英文别名: 1-ethyl-4-hydroxypiperazine
• CAS: 75210-67-2
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: BMPSJXSTWNSUSD-UHFFFAOYSA-N

物化性质

• 沸点：
  206.5±29.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 4,4,5,5, Tetrasubstituted imidazolines
  申请人：Ding Qingjie

  公开号：US20070129416A1

  公开（公告）日：2007-06-07

  There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are herein described. The compounds exhibit activity as anticancer agents.

  提供了一种公式I的化合物以及其药用可接受的盐和酯，其中X1，X2，R1，R2，R3，R4，R5和R6如本文所述。这些化合物作为抗癌药物表现活性。
• [EN] CHIRAL CIS-IMIDAZOLINES<br/>[FR] CIS-IMIDAZOLINES CHIRALES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009047161A1

  公开（公告）日：2009-04-16

  There are provided compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are as herein described, processes for obtaining said compounds and pharmaceutical preparations containing them. These compounds are useful as anticancer agents, in particular as agents in the treatment of solid tumors.

  提供了式（I）的化合物，或其药学上可接受的盐，其中X、Y、Z、V1、V2、R1、R2、R3、R4和R5如本文所述，获得该化合物的方法以及含有它们的药物制剂。这些化合物可用作抗癌剂，特别是作为固体肿瘤治疗中的药物。
• [EN] QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE<br/>[FR] INHIBITEURS DE LA QUINOLÉINE DE RAD52 ET MÉTHODES D'UTILISATION
  申请人：UNIV DREXEL

  公开号：WO2021067604A1

  公开（公告）日：2021-04-08

  The present disclosure related to compounds of Formula I and Formula I and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating RAD51 activity and may be used in the treatment of disorders in which RAD51 activity is implication, such as a cancer.

  本公开涉及到Formula I和Formula I的化合物及其药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于调节RAD51活性，并可用于治疗RAD51活性参与的疾病，如癌症。
• 2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity
  申请人：Koch Melle

  公开号：US20060052331A1

  公开（公告）日：2006-03-09

  The present invention relates to 2-substituted-6-trifluoromethyl purine derivatives as selective adenosine antagonists, in particular adenosine-A 3 receptor antagonists, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said purine derivatives. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.

  本发明涉及作为选择性腺苷拮抗剂的2-取代-6-三氟甲基嘌呤衍生物，特别是腺苷A3受体拮抗剂，以及用于制备这些化合物的方法和用于合成所述嘌呤衍生物的新型中间体。这些化合物具有一般式（1），其中符号具有规范中给定的含义。
• Carbon dioxide absorbent and apparatus of separating and recovering carbon dioxide
  申请人：Kabushiki Kaisha Toshiba

  公开号：US10625200B2

  公开（公告）日：2020-04-21

  A carbon dioxide absorbent of an embodiment includes a chain amine, a cyclic amine, and an acid. The chain amine is a compound expressed by Formula (1) of FIG. 1. R1 in Formula (1) is hydrogen or an alkyl chain having at least one hydroxyl group and 1 to 7 carbon atoms. R2 in Formula (1) is an alkyl chain having at least one hydroxyl group and 1 to 7 carbon atoms. R3 in Formula (1) is hydrogen, a straight alkyl chain having 1 to 7 carbon atoms, a branched alkyl chain having 1 to 7 carbon atoms, or a cyclic alkyl chain having 5 to 7 carbon atoms.

  一种实施例的二氧化碳吸收剂包括一种链胺、一种环胺和一种酸。链胺是由图1的公式（1）表示的化合物。公式（1）中的R1是氢或具有至少一个羟基和1至7个碳原子的烷基链。公式（1）中的R2是具有至少一个羟基和1至7个碳原子的烷基链。公式（1）中的R3是氢、具有1至7个碳原子的直链烷基链、具有1至7个碳原子的支链烷基链或具有5至7个碳原子的环烷基链。